



## Correction: Catalytic asymmetric hydrometallation of cyclobutenes with salicylaldehydes

F. Wieland Goetzke,<sup>a</sup> Mireia Sidera<sup>b</sup> and Stephen P. Fletcher<sup>\*a</sup>


Cite this: *Chem. Sci.*, 2022, 13, 1177

DOI: 10.1039/d1sc90265b

rsc.li/chemical-science

Correction for 'Catalytic asymmetric hydrometallation of cyclobutenes with salicylaldehydes' by F. Wieland Goetzke *et al.*, *Chem. Sci.*, 2022, DOI: 10.1039/d1sc06035j.

The authors regret that the absolute stereochemistry in Scheme 1 presented in the original manuscript was incorrect. The correct version of Scheme 1 is shown below.



**Scheme 1** Asymmetric hydroacylation of cyclobutenes with different salicylaldehydes.<sup>a</sup> <sup>a</sup>[Rh(cod)OH]<sub>2</sub> (2.5 mol%), MeDuphos (6 mol%), cyclobutene **2** (0.6 mmol), salicylaldehyde **1** (0.4 mmol), PhMe (0.2 M), 1–4 h. <sup>b</sup>Increased catalyst loading of [Rh(cod)OH]<sub>2</sub> (5 mol%) and MeDuphos (12 mol%). <sup>c</sup>Diastereomeric ratios of the unpurified reaction mixtures determined by <sup>1</sup>H NMR spectroscopy. All yields refer to isolated yields of the major *trans*–*cis* diastereomer. Enantiomeric excesses determined by SFC analysis on a chiral non-racemic stationary phase.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

<sup>a</sup>Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK. E-mail: stephen.fletcher@chem.ox.ac.uk

<sup>b</sup>Vertex Pharmaceuticals (Europe) Ltd, 86–88 Jubilee Avenue, Milton Park, Abingdon, OX14 4RW, UK

